Dr. Preeshagul on Education for Biosimilars in Oncology

Isabel Preeshagul, DO, MBS
Published: Tuesday, Oct 22, 2019



Isabel Preeshagul, DO, MBS, a thoracic medical oncologist and assistant attending at Memorial Sloan Kettering Cancer Center, discusses the need for more information about using biosimilars when treating patients with cancer.

Preeshagul finds that using biosimilars can be challenging due to a lack of information regarding what biosimilar drugs have been approved and when they should be implemented in a patient’s treatment course.

In order to get more physicians to use or consider using these types of agents, Preeshagul suggests improving the educations surrounding biosimilars. There should be guidance to aid oncologists through the implementation of the biosimilar in practice, Preeshagul concludes.
SELECTED
LANGUAGE


Isabel Preeshagul, DO, MBS, a thoracic medical oncologist and assistant attending at Memorial Sloan Kettering Cancer Center, discusses the need for more information about using biosimilars when treating patients with cancer.

Preeshagul finds that using biosimilars can be challenging due to a lack of information regarding what biosimilar drugs have been approved and when they should be implemented in a patient’s treatment course.

In order to get more physicians to use or consider using these types of agents, Preeshagul suggests improving the educations surrounding biosimilars. There should be guidance to aid oncologists through the implementation of the biosimilar in practice, Preeshagul concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x